This study investigated the heritability of chronic cough, examining whether individuals with chronic cough are more likely to have offspring who also develop cough, and whether this association varies by cough type (productive vs. nonproductive).

The RHINESSA Generation Study included 7,155 parents aged 30-54 who completed detailed questionnaires in 2000 and 2010, and 8,176 offspring aged ≥20 who completed similar questionnaires between 2012-2019. Chronic cough was classified as either productive or nonproductive. Mixed-effects logistic regression analyses were conducted to assess the associations between parental and offspring cough, adjusting for multiple factors including offspring age, sex, body mass index, smoking history, asthma, rhinitis, gastroesophageal reflux, and parental smoking.

Results indicated that offspring of parents with nonproductive cough had a higher prevalence of nonproductive cough (11%) compared to those with parents without nonproductive cough (7%), with an adjusted odds ratio (aOR) of 1.59 (95% CI: 1.20-2.10). Similarly, offspring of parents with productive cough had a higher prevalence of productive cough (14%) compared to those with non-productive cough parents (11%), with an aOR of 1.34 (95% CI: 1.07-1.67). No significant associations were found between mismatched cough types.

These findings suggest that chronic cough, independent of asthma, may be a distinct heritable trait with type-specific transmission patterns.

Recent research indicated that Eladis® exhibited overall effectiveness and a statistically significant superiority compared to the placebo. The data from this study were presented in the journal Terapevticheskii arkhiv.

This phase III clinical trial enrolled 250 individuals aged 18 to 65 years suffering from acute respiratory viral infections with acute bronchitis or upper respiratory tract involvement. Participants were randomly assigned into two groups of 125: one group received Eladis® (40 mg tablets), while the other group received a placebo. The study drugs were administered as one tablet twice daily for a duration of seven to fourteen days. Following the treatment, patients were followed up (on day 7±2) to evaluate the therapy effects on the frequency and intensity of daytime and nighttime cough, the frequency of coughing episodes, the severity of cough, the duration until clinical resolution of cough, and the effect on the severity of the main symptoms associated with acute respiratory viral infections.

Significant differences were observed among the study groups in the percentage of patients who achieved a reduction in coughing attack frequency by 50% or more by day five (p value <0.0001). Additionally, the Eladis® group demonstrated clinical resolution of cough two days earlier, with a median time of six days compared to eight days in the placebo group. By day five of treatment, there was a substantial decrease in both the frequency and severity of cough attacks, exceeding 3.5 points. All these effects were correlated with the drug's high safety profile.

Therefore, Eladis® demonstrated overall efficacy and a statistically significant benefit in comparison to the placebo.

Recent research indicated that Eladis® exhibited overall effectiveness and a statistically significant superiority compared to the placebo. The data from this study were presented in the journal Terapevticheskii arkhiv.

This phase III clinical trial enrolled 250 individuals aged 18 to 65 years suffering from acute respiratory viral infections with acute bronchitis or upper respiratory tract involvement. Participants were randomly assigned into two groups of 125: one group received Eladis® (40 mg tablets), while the other group received a placebo. The study drugs were administered as one tablet twice daily for a duration of seven to fourteen days. Following the treatment, patients were followed up (on day 7±2) to evaluate the therapy effects on the frequency and intensity of daytime and nighttime cough, the frequency of coughing episodes, the severity of cough, the duration until clinical resolution of cough, and the effect on the severity of the main symptoms associated with acute respiratory viral infections.

Significant differences were observed among the study groups in the percentage of patients who achieved a reduction in coughing attack frequency by 50% or more by day five (p value <0.0001). Additionally, the Eladis® group demonstrated clinical resolution of cough two days earlier, with a median time of six days compared to eight days in the placebo group. By day five of treatment, there was a substantial decrease in both the frequency and severity of cough attacks, exceeding 3.5 points. All these effects were correlated with the drug's high safety profile.

Therefore, Eladis® demonstrated overall efficacy and a statistically significant benefit in comparison to the placebo.

A recent study showed that the use of respiratory distress symptom intervention (RDSI) has shown to be an effective and low-risk intervention in aiding the management of the respiratory distress symptom cluster in individuals diagnosed with lung cancer. This study’s findings were published in the journal, BMJ Supportive & Palliative Care.

A total of 263 patients diagnosed with lung cancer were enrolled in this clinical trial, with 132 patients assigned to receive RDSI and 131 patients assigned to receive standard care. To be eligible for the trial, participants had to self-report experiencing adverse effects in their daily lives from at least two out of the three symptoms, in any combination. The outcomes measured were the changes in each symptom within the cluster, namely Dyspnoea-12 (D-12), Functional Assessment of Chronic Illness-Fatigue, and Manchester Cough in Lung Cancer (MCLC) at the 12-week mark.

Nearly 60% of the participants reported experiencing all three symptoms at the baseline. By the end of the trial, there was a total attrition of 109 participants (41.4%). When compared to the control group, the RDSI group demonstrated a statistically significant improvement in D-12 (p=0.007) and MCLC (p<0.001). Each outcome reached the minimal clinically important difference (MCID): MCLC -5.49 (MCID >3), D-12 -4.13 (MCID >3), and FACIT-F 4.91 (MCID >4).

Thus, RDSI has proven its effectiveness and safety in supporting the management of the respiratory distress symptom cluster in patients with lung cancer. However, it is important to consider the significant attrition observed in the study while interpreting these findings.

According to a recent study, thymus vulgaris (TV) syrup may be an effective adjunctive therapy in the management of asthma exacerbations in children. This study’s results were published in the journal, Allergologia et Immunopathologia.

In this triple blinded, randomized clinical trial, a total of 60 children aged between 5 and 12, who were experiencing asthma exacerbations, were divided into two groups. The intervention group, consisting of 30 children, received TV powder in syrup form at a dosage of 20 mg/kg every 8 hours, in addition to their regular medical treatment, for a duration of one week. On the other hand, the control group, also comprising 30 children, received a placebo syrup along with their regular medical treatment. At the end of the week, clinical and laboratory symptoms, as well as spirometry data, were recorded again for both groups.

Following the intervention, there was a decrease in activity-induced cough, with a statistically significant difference observed between the two groups (p = 0.042). Analysis of spirometry data revealed a significant variance in forced expiratory volume in 1 second (FEV1) between the two groups post-intervention (p = 0.048).

Thus, it can be concluded that TV syrup may be a beneficial supplementary treatment in the control of asthma exacerbations among children.